Randomised trial of N-acetylcysteine in laparoscopic bariatric surgery

The Effect of Intraoperative N-Acetylcysteine on Hepatocellular Injury During Laparoscopic Bariatric Surgery: A Randomised Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN81349394

Enrollment

Registered

2008-02-28

Start date

2009-04-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid obesity /non-alcoholic fatty liver disease Nutritional, Metabolic, Endocrine Morbid obesity /non-alcoholic fatty liver disease

Interventions

Treatment group: N-acetylcysteine 150 mg/kg lean body weight, intravenously as an infusion during surgery Control group: No intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or Female 2. Aged 18 to 65 3. National Institute of Clinical Excellence criteria for morbid obesity surgery: BMI >40 or BMI >35 with obesity related complications

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. History of chronic liver disease, including viral hepatitis, haemachromatosis, alcoholic liver disease or known alcohol intake >20g/day 3. Previous liver surgery, e.g., resection, orthotopic transplantation 4. Psychiatric illness, including anxiety, mood and eating disorders 5. Bleeding tendency or anticoagulant medications 6. Known allergies to N-acetylcysteine or related compounds

Design outcomes

Primary

Measure	Time frame
The extent of hepatocellular damage and its clinical effect, measured at post-operative days 1, 2, 3 and at 6 weeks post surgery.	—

Secondary

Measure	Time frame
To elucidate the mechanisms of intraoperative hepatocellular damage and the effects (if any) of N-acetylcysteine.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026